Tvardi Therapeutics Inc., a clinical-stage biopharmaceutical company, has successfully completed its merger with Cara Therapeutics. As a result of the transaction, Tvardi received approximately $23.8 million in net cash from Cara, enhancing its financial position. This merger, combined with a previous private placement financing of $28.3 million, strengthens Tvardi's capability to fund its operations. The company now anticipates having sufficient resources to sustain its activities into the second half of 2026. The merger is expected to heighten Tvardi's visibility and access to capital, propelling its development programs, including those targeting idiopathic pulmonary fibrosis and hepatocellular carcinoma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.